| Oct 9 |
'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months
|
| Oct 8 |
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
|
| Oct 7 |
BioAtla: Numerous Catalysts Coming In Q4
|
| Oct 4 |
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
|
| Oct 1 |
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
|
| Sep 23 |
BioAtla out-licenses BA3362 to Context Therapeutics
|
| Sep 23 |
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
|
| Sep 16 |
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European ...
|
| Sep 9 |
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
|
| Sep 4 |
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky
|
